ASMB
NASDAQAssembly Biosciences Inc.
Price$20.12+0.04 (+0.20%)
01:30 PM07:45 PM
News · 26 weeks40-67%
2026-04-192026-10-11
Mix1090d
- Other6(60%)
- SEC Filings3(30%)
- Analyst1(10%)
Latest news
25 items- PRAssembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced that two posters featuring new Phase 1a data from its ABI-6250 program will be presented at The Liver Meeting® 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 5-9, 2026, in Denver, Colorado. "The Phase 1a findings support ABI-6250’s safety profile and demonstrate potent target engagement, and we are pleased the pharmacodynamic analysis was recognized as a Poster of Distinction," said Anuj Gaggar, M.D.,
- PRAssembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment ConferenceSOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026. A live webcast will be available on the Events and Presentations section of Assembly Bio’s website, and a replay will be accessible following the event. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/events-presentations. About Assembly Biosciences Assembly Biosciences is
- PRAssembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes – – Cash runway remains projected into 2029, including the first $75 million collaboration extension fee from Gilead payable in Q4 2026 – SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced it has exercised its option to share 40% of the development costs and profits in the United States for its herpes simplex virus (HSV) helicase-primase inhibitor (HPI) program for recurrent genital he
- ANALYSTUBS initiated coverage on Assembly Biosciences with a new price targetUBS initiated coverage of Assembly Biosciences with a rating of Buy and set a new price target of $52.00
- SECSEC Form S-8 filed by Assembly Biosciences Inc.S-8 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
- SECSEC Form 10-Q filed by Assembly Biosciences Inc.10-Q - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
- SECAssembly Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
- PRAssembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 million gross financing to support advancement of pipeline programs through key development milestones – – GS-1179 (formerly ABI-1179) selected to advance in HSV HPI program, with Phase 2 initiation expected by year-end 2026 – – Cash runway projected into 2029, including first $75 million Gilead collaboration extension payment due in Q4 2026 – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics target
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Assembly Biosciences Inc.SCHEDULE 13G/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Assembly Biosciences Inc.SCHEDULE 13G/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
- INSIDERPFO and PAO Bjorkquist Jeanette M sold $674 worth of shares (29 units at $23.25), decreasing direct ownership by 0.20% to 14,560 units (SEC Form 4) (tax withholding)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERChief Medical Officer Gaggar Anuj was granted 14,000 shares, increasing direct ownership by 49% to 42,688 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERChief Manufacturing Officer White Nicole S was granted 14,000 shares, increasing direct ownership by 41% to 48,145 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Mchutchison John G4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Mahony Susan4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Johnson-Pratt Lisa4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Houghton Michael4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Consylman Gina4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Altig Anthony E4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERPFO and PAO Bjorkquist Jeanette M was granted 3,500 shares, increasing direct ownership by 32% to 14,589 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERChief Scientific Officer Delaney William E Iv was granted 14,000 shares, increasing direct ownership by 30% to 60,330 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERCEO and President Okazaki Jason A was granted 50,750 shares, increasing direct ownership by 45% to 163,354 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- SECAssembly Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
- PRAssembly Biosciences Announces Upcoming Investor Conference PresentationsSOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will participate in fireside chats at two upcoming investor conferences: Jefferies 2026 Global Healthcare ConferenceDate: June 3, 2026Time: 4:20 p.m. ET Goldman Sachs 47th Annual Global Healthcare ConferenceDate: June 8, 2026Time: 8:40 a.m. ET To register for either webcast, please visit the Events and Presentations section of Assembly Bio's website at: https://investor.assemblybio.com/events-presentations. A replay will be accessible following each
- INSIDERLarge owner Gilead Sciences, Inc. was granted 471,698 shares, increasing direct ownership by 10% to 4,977,089 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
ASMB FAQ
7 questionsWhat does Assembly Biosciences Inc. do?
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd.; and Arbutus Biopharma Corporation, as well...Where does ASMB stock trade?
Assembly Biosciences Inc. (ASMB) is listed on NASDAQ.What sector and industry is ASMB in?
Assembly Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Assembly Biosciences Inc. go public?
Assembly Biosciences Inc. (ASMB) completed its IPO in 2010.What are analysts saying about ASMB?
Assembly Biosciences Inc. has had 7 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-09-01.What companies are similar to ASMB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ASMB side-by-side with any of them on Quantisnow.How can I track ASMB on Quantisnow?
Quantisnow aggregates Assembly Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ASMB to receive live email and push alerts on every new disclosure.